Literature DB >> 114584

T lymphocyte-mediated suppression of myeloma function in vitro. I. Suppression by allogeneically activated T lymphocytes.

A K Abbas.   

Abstract

Alloreactive cells generated by in vitro stimulation of C57BL/6 (H-2b) spleen lymphocytes with irradiated MOPC 315 or MOPC 104E(H-2d) cells were shown to lyse 51Cr-labeled myeloma targets at high effector:target ratios under conditions of inefficient cell contact, the alloreactive cells cause variable and frequently minimal lysis of myeloma targets but markedly suppress antibody secretion even by viable myeloma cells. The suppressor cells are radioresistant T cells lacking I-J subregion-encoded surface determinants; their precursors are insensitive to cyclophosphamide; suppression is H-2 specific and not mediated by secreted factors; and the suppression is blocked by Cytochalasin B, a known inhibitor of T cell-mediated cytolysis. These properties are typical of cytolytic T lymphocytes (CTL) and not of defined suppressor T cells, suggesting that inhibition of myeloma function probably represents a pre-lytic effect of the alloreactive CTL, although a CTL-like suppressor cell effect cannot be definitively excluded. These results are discussed with reference to the possible relationships between suppressor and cytolytic T lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 114584

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  Human B cell growth factors overcome T cell-mediated inhibition of specific antibody production: a possible mechanism for the exacerbation of autoimmune disease.

Authors:  M K Brenner; M E North
Journal:  Clin Exp Immunol       Date:  1983-06       Impact factor: 4.330

2.  T lymphocytes specific for immunoglobulin allotype. I. Igh-1b-specific T cells demonstrated by suppression in vivo and cytotoxicity in vitro.

Authors:  H R Snodgrass; D B Wilson; M J Bosma
Journal:  J Exp Med       Date:  1981-08-01       Impact factor: 14.307

3.  T lymphocyte-mediated suppression of myeloma function in vitro. II. Evidence for regulation of hapten-binding myelomas by syngeneic hapten-specific cytolytic T lymphocytes.

Authors:  A K Abbas; S E Ratnofsky; S J Burakoff
Journal:  J Exp Med       Date:  1980-08-01       Impact factor: 14.307

4.  Regulation of B cell lymphomagenesis by a malignant Qal+ inducer T cell clone.

Authors:  C L Reinisch; A P Sing; E R Bacon; R B Corley; R K Gershon
Journal:  J Exp Med       Date:  1984-03-01       Impact factor: 14.307

5.  T lymphocyte-mediated suppression of myeloma function in vitro. III. Regulation of antibody production in hybrid myeloma cells by T lymphocytes.

Authors:  A K Abbas; S J Burakoff; M L Gefter; M I Greene
Journal:  J Exp Med       Date:  1980-10-01       Impact factor: 14.307

6.  Lymphocyte recovery and clinical response in multiple myeloma patients receiving interferon alpha 2 beta after intensive therapy.

Authors:  B C Millar; J B Bell; R L Powles
Journal:  Br J Cancer       Date:  1996-01       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.